Details for Patent: 10,383,961

Which drugs does patent 10,383,961 protect, and when does it expire?

Patent 10,383,961 protects DETECTNET and is included in one NDA.

This patent has eleven patent family members in six countries.

Summary for Patent: 10,383,961

Title:	PET tracer for imaging of neuroendocrine tumors
Abstract:	There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Inventor(s):	Andreas Kjaer, Ulrich Knigge, Liselotte Højgaard, Palle Rasmussen
Assignee:	Somscan Aps
Application Number:	US16/179,453
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,383,961

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes	10,383,961					USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

Foreign Priority and PCT Information for Patent: 10,383,961

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2011 00654	Aug 31, 2011

International Family Members for US Patent 10,383,961

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	2750717
Denmark	3536346
European Patent Office	2750717
European Patent Office	3536346